Full text is available at the source.
Abstract
One hundred and eighteen randomized controlled trials were analyzed, showing no clinical differences between the standard CFC-containing pMDI and 12 other hand-held inhaler devices.
- Short-acting beta(2)-agonist bronchodilators delivered via standard CFC-containing pMDIs are as effective as other inhaler devices in stable asthma patients.
- No significant differences were observed in clinical outcomes between the standard pMDI and alternative inhalers across various measures.
- The analysis indicates that a 1:1 or 2:1 dosing ratio does not affect the clinical efficacy of the inhaler devices.
- Cost-effective inhaler options should be prioritized for patients, as effectiveness appears consistent across devices.
- Pharmaceutical companies are encouraged to provide clinical outcome data to regulatory bodies for dosing schedules exceeding a 1:1 ratio.
Simplified